Pyxis Oncology (PYXS) Change in Accured Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Change in Accured Expenses data on file, last reported at $552000.0 in Q4 2025.

• On a quarterly basis, Change in Accured Expenses rose 120.54% year-over-year to $552000.0 in Q4 2025; TTM through Dec 2025 was -$2.8 million, a 69.04% decrease from a year earlier, with the FY2025 full-year figure at -$2.8 million, down 69.04% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at $552000.0, down from $1.3 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for PYXS reached as high as $10.5 million in Q1 2022 and fell as low as -$13.3 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$77350.0 across 5 years, with a median of $464500.0 in 2021.
• On a YoY basis, Change in Accured Expenses climbed as much as 2246.64% in 2022 and fell as far as 2762.07% in 2022.
• Year by year, Change in Accured Expenses stood at $1.9 million in 2021, then surged by 227.54% to $6.3 million in 2022, then plunged by 157.99% to -$3.7 million in 2023, then grew by 26.62% to -$2.7 million in 2024, then surged by 120.54% to $552000.0 in 2025.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $552000.0 in Q4 2025, $1.3 million in Q3 2025, and -$3.4 million in Q2 2025.